ImmuPharma (LON:IMM) Stock Price Down 31.4% – Should You Sell?

ImmuPharma plc (LON:IMMGet Free Report)’s stock price dropped 31.4% during trading on Monday . The stock traded as low as GBX 6.70 and last traded at GBX 6.70. Approximately 27,337,178 shares changed hands during trading, an increase of 242% from the average daily volume of 7,982,150 shares. The stock had previously closed at GBX 9.76.

ImmuPharma Stock Performance

The firm has a fifty day moving average of GBX 10.96 and a 200 day moving average of GBX 5.84. The firm has a market capitalization of £33.68 million, a PE ratio of -7.53 and a beta of 1.53.

About ImmuPharma

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzorâ„¢), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Read More

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.